19 results about "Lanosterol" patented technology

The application discloses a kit for diagnosing systemic lupus erythematosus, which is lanosterol lipid metabolite key enzyme CYP51A1, the expression amount of the transcription level of the lanosterol lipid metabolite key enzyme CYP51A1, and the cDNA sequence of the lanosterol lipid metabolite key enzyme CYP51A1 is shown as SEQ ID No. 1. The kit for diagnosing SLE provided by the application comprises CYP51A1 gene primers and primers of a housekeeping gene GAPDH, a standard product and amplification reagents. The application overcomes the defect that SLE gene diagnosis cannot be diagnosed. The application adopts a real-time fluorescent quantitative PCR method, has the characteristics of rapidness, sensitivity, accuracy and the like, the expression of CYP51A1 is detected through real-time fluorescent quantitative PCR, important basis and reference value can be provided for clinical diagnosis of diseases, thus being beneficial to the formulation of a treatment scheme of the disease, and having popularization and application value.

The present invention relates to a pharmaceutical dosage form comprising lanosterol and a derivative thereof, and cyclodextrin, the pharmaceutical dosage form according to one embodiment having an effect of improving water solubility and in vivo absorbability, thereby increasing bioavailability.

The application discloses application of lanosterol derivatives with the following structure in preparation of drugs for treating retinal degenerative diseases. A novel compound, lanosterol derivative L7, is synthesized by reasonably modifying a lanosterol mother nucleus structure, and the bioavailability and retinal targeting property of the lanosterol derivative L7 are significantly improved, and the lanosterol derivative L7 can significantly improve retinal degeneration and shows better safety and effectiveness.

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The present application relates to the technical field of medicine, and provides a lanosterol derivative, a preparation method and application thereof.The structural formula of the lanosterol derivative provided by the present application is shown as formula I or formula II.The lanosterol derivative provided by the present application has both fat solubility and water solubility, can effectively penetrate into the pathological site in the body, and improves the drug utilization degree;the results of examples show that the solubility of the lanosterol derivative provided by the present application in water is obviously higher than that of lanosterol or 25-hydroxy lanosterol, and the lanosterol derivative shows obvious cataract treatment effect in animal body experiments, and has a broad prospect in the preparation of drugs for treating eye diseases or conditions.

The invention belongs to the technical field of medicines, and discloses a preparation method of a series of compounds which have the effect of increasing the content of lanosterol in the brain and have general formulas (I) and (II) as well as a pharmaceutical composition and application of the compounds.

The invention discloses an application of a lanosterol derivative with a structure shown in the specification in preparation of a medicine for treating retinal degenerative diseases: a novel compound lanosterol derivative L7 is synthesized by reasonably modifying a lanosterol mother nucleus structure, so that the bioavailability and the retina targeting property of the lanosterol derivative L7 are remarkably improved; retinal degeneration can be remarkably improved, and better safety and effectiveness are shown.

The present application relates to the technical field of medicine and provides a lanosterol derivative, a preparation method therefor and a use thereof. The structural formula of the lanosterol derivative provided by the present application is as shown in formula I or II. The lanosterol derivative provided by the present application has both lipid solubility and water solubility, and can effectively penetrate into the pathological site in the body, thereby improving the drug utilization rate. The results of embodiments show that the lanosterol derivative provided by the present application has a significantly higher solubility in water than lanosterol or 25-hydroxylanosterol and shows a significant therapeutic effect on a cataract in animal in vivo experiments. Therefore, the derivative has wide prospects in the preparation of drugs for treating eye diseases or conditions.

The invention relates to the technical field of biology, in particular to construction and application of a recombinant strain for synthesizing veratrazine and steroid precursors of the veratrazine, and the steroid precursors comprise squalene, ergosterol, lanosterol, 22R-hydroxy cholesterol, 22R, 26-dihydroxy cholesterol and 22-hydroxy-26-amino-cholesterol. The recombinant strain provided by the invention can efficiently express steroid precursors, for example, the content of lanosterol reaches 172mg / L and is increased by about 170 times compared with that of an original strain, the yield of 22R-hydroxycholesterol reaches 3482.83 mu g / L, the yield of 22R, 26-dihydroxycholesterol reaches 1003.05 mu g / L, veratrazine can be efficiently synthesized, and the yield of veratrazine reaches 265.38 mu g / L.

The application provides an eye preparation for preventing and treating cataract by eye drop, which is composed of an active substance for treating eye diseases and a pharmaceutically acceptable carrier or excipient; the active substance for treating eye diseases is oxidized cholestanol, including lanosterol or 25-hydroxycholestanol; the pharmaceutically acceptable carrier or excipient contains a surfactant, a tackifier, a cosolvent and a solvent; the content of the oxidized cholestanol in the preparation is 0.01-5 mg / mL; the mass ratio of the surfactant, the tackifier, the cosolvent and the oxidized cholestanol is (1-300):(1-100):(100-3000):1, and the rest is the solvent. After the eye drop of the preparation, the active substance can be selectively enriched in the lens of experimental animals, so that the effect of treating cataract can be accurately exerted, and the active substance is not distributed in the aqueous humor and the vitreous body, thereby avoiding the toxic and side effects on other eye tissues and the whole body. The application solves the technical problem which people in the field of ophthalmic drug delivery have been eager to solve but have failed to obtain success, and has a very high clinical application value and social value.

The invention belongs to the technical field of synthetic biology, and particularly relates to recombinant escherichia coli for efficiently biosynthesizing lanosterol as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: introducing exogenous squalene synthase (SQS), squalene epoxidase (SE) and oxidized squalene cyclase (OSC) genes into escherichia coli to construct a complete lanosterol synthesis route; the method comprises the following steps of: enhancing MEP pathway rate-limiting enzymes, namely 1-deoxy-D-xylulose-5-phosphate synthase (DXS), isopentenyl pyrophosphate isomerase (IDI) and farnesyl pyrophosphate synthase (FPS), so as to increase precursor supply, and further regulating and controlling the expression of key enzyme genes by adopting an arabinose promoter (PBAD). The lanosterol yield of the constructed engineering bacterium BW-2 reaches 8.02 mg / L and is increased by 40 times compared with that of an initial strain, and a brand new technical scheme is provided for green and efficient industrial production of lanosterol.

This invention provides the application of lanosterols in the preparation of feed additives for bony fish and the feed itself, including lanosterols or their feed-acceptable esters, in the preparation of feed additives for bony fish to improve the growth performance, muscle quality, and physiological health of bony fish, including enhancing their antioxidant capacity and / or immunity. This invention provides a novel, efficient, and cost-optimized functional additive for bony fish feed, offering an effective cholesterol alternative or supplement to reduce feed costs; simultaneously, it significantly improves the growth performance and muscle quality of bony fish, enhances immune function and stress resistance, thereby improving aquaculture efficiency and feed utilization.

This invention provides the application of lanosterols in the preparation of crustacean feed additives and related feeds, including lanosterols or their feed-acceptable esters, in the preparation of crustacean feed additives to improve the growth performance and maintain the physiological health of crustaceans, including regulating lipid metabolism, enhancing antioxidant capacity, and / or improving digestive enzyme activity. This invention provides a novel, efficient, and cost-optimized functional additive for crustacean feed, offering an effective cholesterol alternative or supplement to reduce feed costs; and significantly improving the growth performance of crustaceans under low-fishmeal feed conditions while systematically regulating and maintaining their physiological health.

The invention discloses a process for affinity separation of active components in inonotus obliquus by using a VEGFR2 extracellular domain and application, and relates to the technical field of active component extraction.The process comprises the steps that eight active components including echinacoside, trilliin, typhaenoside, hederagenin, asiaticoside, lanosterol, betulin and aster ketone are selected; the inhibition effect of the compound on cervical cancer cells is studied. The method comprises the following steps: taking a sample to be detected, taking a detection solution, carrying out lauryl sodium sulfate-polyacrylamide gel electrophoresis and Western blot analysis, determining the protein expression quantity of VEGFR-2 related pathways, and researching the regulating effects of trillioside, betulin, hederagenin and lanosterol on a PI3K / AKT signal pathway, a PLC gamma / ERK signal pathway, Bad protein, Caspase-9 protein and Cleaved Caspase-9 protein of SiHa cells.

The present disclosure relates to a pharmaceutical formulation including lanosterol, a derivative thereof, and cyclodextrin. The pharmaceutical formulation, according to an aspect, exhibits enhanced water solubility and absorption in the body, and thus has the effect of increasing bioavailability.

The invention discloses a nitric oxide donor type lanosterol derivative as shown in a formula I and a preparation method and application thereof, and the nitric oxide donor type lanosterol derivative has dual functions of reducing intraocular pressure and protecting optic nerves and can be used for preparing a medicine for treating glaucoma diseases. Wherein R is selected from one of C2-C5 straight chain alkylene groups.

The application discloses a process for affinity separation of active ingredients in Inonotus obliquus by using an extramembrane region of VEGFR2 and application thereof, and relates to the technical field of active ingredient extraction. Eight active ingredients, namely echinacoside, strophanthin, typhonioside, hederagenin, asiaticoside, lanosterol, betulinol and shionin, are selected to study the inhibiting effect of the active ingredients on cervical cancer cells. The detection liquid is taken to perform sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blot analysis, the expression amount of VEGFR-2 related pathway proteins is determined, and the regulation effects of strophanthin, betulinol, hederagenin and lanosterol on the PI3K / AKT signal pathway, the PLC gamma / ERK signal pathway, Bad protein, Caspase-9 protein and Cleaved Caspase-9 protein of SiHa cells are studied.

The invention discloses a recombinant Yarrowia lipolytica engineering strain for producing ergosterol and application of the recombinant Yarrowia lipolytica engineering strain, and belongs to the technical field of genetic engineering and bioengineering. According to the method, sterol synthesis route genes are screened, the speed limiting step is determined, high-yield ergosterol is preliminarily achieved through combined expression, the flow direction of carbon metabolic flow is further pulled through lipid droplet engineering and cell area chamber engineering, and the yield of ergosterol is increased. On the basis of enzyme modification engineering, the catalytic efficiency of the ERG11 on the lanosterol is improved through substrate channel engineering and proton-dependent catalytic path construction. Through multi-copy integration of the genes in the speed limiting step, the yield of ergosterol in a shake flask of the constructed engineering strain reaches 433.1 mg / L, and the yield of ergosterol in a 5L fermentation tank system reaches 4.58 g / L.

This invention, entitled "A Pharmaceutical Formulation Containing Lanosterol and Its Preparation Method," belongs to the field of ophthalmic pharmaceutical formulation technology. The technical problem to be solved is to provide a pharmaceutical formulation containing lanosterol, while simultaneously addressing issues such as the solubility and stability of lanosterol compounds, and the use of irritating raw materials such as organic solvents or preservatives, or combinations thereof. The key technical points are that the raw materials of the pharmaceutical formulation include an active ingredient and excipients. The active ingredient is composed of lanosterol compounds and carnosine derivatives. The lanosterol compounds include at least one of lanosterol and dihydrolanosterol. The excipients include stabilizers, triglyceride derivatives, pH adjusters, and thickeners.